Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17
Year: 2015
Type: article
Abstract: The protease ADAM17 (a disintegrin and metalloproteinase 17) catalyzes the shedding of various transmembrane proteins from the surface of cells, including tumor necrosis factor (TNF) and its receptors. Liberation of TNF receptors (TNFRs) from cell surfaces can dampen the cellular response to TNF, a cytokine that is critical in the innate immune response and promotes programmed cell death but can also promote sepsis. Catalytically inactive members of the rhomboid family of proteases, iRhom1 and iRhom2, mediate the intracellular transport and maturation of ADAM17. Using a genetic screen, we found that the presence of either iRhom1 or iRhom2 lacking part of their extended amino-terminal cytoplasmic domain (herein referred to as ΔN) increases ADAM17 activity, TNFR shedding, and resistance to TNF-induced cell death in fibrosarcoma cells. Inhibitors of ADAM17, but not of other ADAM family members, prevented the effects of iRhom-ΔN expression. iRhom1 and iRhom2 were functionally redundant, suggesting a conserved role for the iRhom amino termini. Cells from patients with a dominantly inherited cancer susceptibility syndrome called tylosis with esophageal cancer (TOC) have amino-terminal mutations in iRhom2. Keratinocytes from TOC patients exhibited increased TNFR1 shedding compared with cells from healthy donors. Our results explain how loss of the amino terminus in iRhom1 and iRhom2 impairs TNF signaling, despite enhancing ADAM17 activity, and may explain how mutations in the amino-terminal region contribute to the cancer predisposition syndrome TOC.
Source: Science Signaling
Authors: Sathish K. Maney, David R. McIlwain, Robin Polz, Aleksandra A. Pandyra, Balamurugan Sundaram, Dorit Wolff, Kazuhito Ohishi, Thorsten Maretzky, Matthew A. Brooke, Astrid Evers, Ananda A. Jaguva Vasudevan, Nima Aghaeepour, Jürgen Scheller, Carsten Münk, Dieter Häussinger, Tak W. Mak, Garry P. Nolan, David P. Kelsell, Carl P. Blobel, Karl S. Lang, Philipp A. Lang
Institutions: Düsseldorf University Hospital, Heinrich Heine University Düsseldorf, Stanford University, University of Duisburg-Essen, The University of Osaka, Hospital for Special Surgery, University of London, Queen Mary University of London, Blizard Institute, University Health Network, Cornell University, Weill Cornell Medicine
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
Funders: U.S. Department of Defense, Alexander von Humboldt-Stiftung, Cancer Research UK, Deutsche Forschungsgemeinschaft, National Institutes of Health, Canadian Institutes of Health Research, Medical Research Council, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
Awards: Highly multiplexed ion-beam tissue molecular imaging with sub-micron resolution, G1263991214, G1376189913, Systems Approach to Immunity and Inflammation, G2070509383, G2321374631, Modeling the Role of Differentiation in Cancer Progression, G291137109, G2956791797, G3449621863, G348570934, G3546235496, G4371741117, G5091808919, G5201313865, Integrating mass cytometric and transcriptomic profiles of solid tumors, MicroRNAs as T cell sensitivity Rheostats, iRHOM mediated ADAM17 regulation in cutaneous disease and repair, iRhoms 1 and 2: Key regulators of ADAM17-dependent EGFR signaling, G614235862, G7104675289, G7422177992, (PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers, G8180072699, G832129709, G853243261, Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro
OpenAlex ID: W2201728328
